Orell Mielke

Abstract Objective To investigate the long-term safety and efficacy of weekly subcutaneous IgPro20 (Hizentra, CSL Behring) in chronic inflammatory demyelinating polyneuropathy (CIDP). Methods In a 48-week open-label prospective extension study to the PATH study, patients were initially started on 0.2 g/kg or on 0.4 g/kg weekly and—if clinically stable—switched to 0.2 g/kg weekly after 24 weeks. Upon CIDP relapse on the 0.2 g/kg dose, 0.4 g/kg was (re)initiated.

M Berger and O Mielke are salaried employees and owners of stock of CSL Behring. Thomas Harbo has received compensation from CSL Behring for recording a video on subcutaneous administration of IgG. The authors wish to thank Jason Hecker and Joanna Musgrove of Meridian Health Communications for compensated technical assistance with preparation and submission of the manuscript.

We thank Ravi Uniyal and colleagues for their comments on our results from the PATH trial1x1van Schaik, IN, Bril, V, van Geloven, N et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol.